AI News NQ Analysis

[KY] Subsidiary Signs Letter of Intent to Acquire Jade Pharmaceutical Co., Ltd.

Key facts

  • [KY] Subsidiary Signs Letter of Intent to Acquire Jade Pharmaceutical Co., Ltd.
  • KY's subsidiary, Chen Yao Medical Management Consulting Co., Ltd., has signed a letter of intent to acquire Jade Pharmaceutical Co., Ltd. for NT$25,000,000. The purpose is to expand domestic pharmacy sales channels and strengthen regional medical services.
  • Source: TWSE
  • Date: Mon Jun 15 2026 09:00:00 GMT+0900 (Japan Standard Time)

Direct answer

KY's subsidiary, Chen Yao Medical Management Consulting Co., Ltd., has signed a letter of intent to acquire Jade Pharmaceutical Co., Ltd. for NT$25,000,000. The purpose is to expand domestic pharmacy sales channels and strengthen regional medical services.

Citation
[KY] Subsidiary Signs Letter of Intent to Acquire Jade Pharmaceutical Co., Ltd. (Mon Jun 15 2026 09:00:00 GMT+0900 (Japan Standard Time)), TWSE
Source
TWSE
Date
Mon Jun 15 2026 09:00:00 GMT+0900 (Japan Standard Time)

AI Summary (NQ-processed)

KY's subsidiary, Chen Yao Medical Management Consulting Co., Ltd., has signed a letter of intent to acquire Jade Pharmaceutical Co., Ltd. for NT$25,000,000. The purpose is to expand domestic pharmacy sales channels and strengthen regional medical services.

AI Analysis

Frequently Asked Questions

Q: Who is KY's subsidiary?
A: It is Chen Yao Medical Management Consulting Co., Ltd.
Q: Who is the acquisition target?
A: It is Jade Pharmaceutical Co., Ltd.
Q: How much is the acquisition amount?
A: It is NT$25,000,000.
Q: What is the purpose of the acquisition?
A: To expand domestic pharmacy sales channels and strengthen regional medical services.
Q: What is the plan after the acquisition?
A: To retain the existing team of Jade Pharmaceutical Co., Ltd. and integrate the marketing and sales channels of both parties.